Dutasteride, a dual inhibitor of both type I and II 5α-reductases, is used to treat male pattern hair loss (MPHL). However, patient response to dutasteride varies in each individual, the cause of which is yet to be identified. To identify genetic variants associated with response to dutasteride treatment for MPHL, a total of 42 men with moderate MPHL who had been treated with dutasteride for 6 months were genotyped and analysed by quantitative linear regression, case-control association tests, and Fisher's exact test. The synonymous single nucleotide polymorphism (SNP) rs72623193 in DHRS9 was most significantly associated with response to dutasteride, followed by the non-synonymous SNP rs2241057 in CYP26B1. Additionally, variants in ESR1, SRD5A1, CYP19A1, and RXRG are suggested to be associated with response to dutasteride. Cumulative effect and interaction among these SNPs were presented in both additive and non-additive models.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6746394 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0222533 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Design of Nanocrystalline Suspension of Dutasteride for Intramuscular Prolonged Delivery.
Nanomaterials (Basel)
November 2024
College of Pharmacy, Dankook University, 119 Dandae-ro, Dongnam-gu, Cheonan 31116, Chungnam, Republic of Korea.
The aim of the study is to formulate an injectable nanocrystalline suspension (NS) of dutasteride (DTS), a hydrophobic 5α-reductase inhibitor used to treat benign prostatic hyperplasia and scalp hair loss, for parenteral long-acting delivery. A DTS-loaded NS (DTS-NS, 40 mg/mL DTS) was prepared using a lab-scale bead-milling technique. The optimized DTS-NS prepared using Tween 80 (0.
View Article and Find Full Text PDFTamsulosin and Dutasteride Combination Therapy for Asian Men With Moderate-to-Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Systematic Review of Clinical Considerations That Influence the Prescription.
J Clin Med Res
September 2024
Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King's College London, London, England, UK.
The goal of combination therapy for moderate-to-severe lower urinary tract symptoms secondary to benign prostatic hyperplasia (LUTS/BPH) is to ease both the dynamic and static symptoms by using agents that have complementary mechanisms of action. Similar to prescribing other drugs, LUTS/BPH combination therapy has been affected by multiple factors. Previous qualitative research discussed the individual perspectives that influenced combination therapy administration.
View Article and Find Full Text PDFEffects of 5α-reductase inhibition by dutasteride on reproductive gene expression and hormonal responses in zebrafish embryos.
Comp Biochem Physiol C Toxicol Pharmacol
January 2025
Environmental Safety Group, Korea Institute of Science & Technology Europe (KIST-EUROPE), 66123 Saarbrücken, Germany; Division of Energy & Environment Technology, University of Science & Technology, 34113 Daejeon, Republic of Korea. Electronic address:
Article Synopsis
- Steroid 5α-reductase (SRD5A) is vital for converting testosterone into dihydrotestosterone (DHT), and its inhibitor dutasteride is used to treat benign prostatic hyperplasia, but it can also negatively affect fish reproduction.
- This study on zebrafish embryos shows that dutasteride exposure reduced levels of DHT, 17β-estradiol (E2), and vitellogenin (VTG), leading to downregulation of reproduction-related genes, indicating a complex relationship between androgens and estrogens.
- The research suggests that the effects of dutasteride may not depend on typical hormonal pathways (and
A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma - the DUCT study protocol.
BMC Cancer
September 2024
Department of Medical Oncology, Radboud Institute for Medical Innovation, Radboud University Medical Center, Geert Grooteplein Zuid 8, Nijmegen, 6525 GA, The Netherlands.
Background: Salivary duct carcinoma (SDC) is a rare and aggressive subtype of salivary gland cancer, frequently associated with incurable recurrences and distant metastases (R/M). Proliferation of SDC relies on androgen receptor (AR) signalling, prompting the use of combined androgen blockade (CAB, i.e.
View Article and Find Full Text PDFDutasteride in the treatment of frontal fibrosing alopecia: Systematic review and meta-analysis.
J Eur Acad Dermatol Venereol
August 2024
Department of Dermatology, College of Medicine, Hanyang University, Hanyang University Guri Hospital, Guri-Si, Korea.
Frontal fibrosing alopecia (FFA) is a scarring alopecia with fronto-temporo-parietal hairline recession. Although no proven treatment for FFA exists, dutasteride has been suggested as a potential treatment option. We aimed to evaluate the therapeutic response of oral dutasteride in FFA patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!